Risk of liver decompensation with cumulative use of mitochondrial toxic nucleoside analogues in HIV/hepatitis C virus coinfection.

Vincent Lo ReBret ZeldowMichael J KallanJanet P TateDena M CarbonariSean HennessyJay R KostmanJoseph K LimMatthew Bidwell GoetzRobert GrossAmy C JusticeJason A Roy

Published in: Pharmacoepidemiology and drug safety (2017)

These findings suggest that cumulative mtNRTI use may increase the risk of hepatic decompensation and death in HIV/HCV coinfection. These drugs should be avoided when alternatives exist for HIV/HCV patients.

Keyphrases

hepatitis c virus
human immunodeficiency virus
antiretroviral therapy
hiv positive
hiv infected
end stage renal disease
hiv testing
hiv aids
newly diagnosed
chronic kidney disease
ejection fraction
prognostic factors
oxidative stress
south africa